Edwards Lifesciences (NYSE:EW) Price Target Raised to $73.00

Edwards Lifesciences (NYSE:EW) had its target price upped by Piper Sandler from $70.00 to $73.00 in a report released on Wednesday,Benzinga reports. The firm currently has a neutral rating on the medical research company’s stock.

Other research analysts have also recently issued research reports about the stock. Royal Bank of Canada upped their target price on shares of Edwards Lifesciences from $80.00 to $85.00 and gave the stock an “outperform” rating in a research report on Thursday, December 5th. Canaccord Genuity Group increased their price objective on Edwards Lifesciences from $63.00 to $68.00 and gave the stock a “hold” rating in a report on Thursday, December 5th. Truist Financial reaffirmed a “hold” rating and set a $78.00 target price (up previously from $70.00) on shares of Edwards Lifesciences in a research note on Thursday, December 5th. Stifel Nicolaus raised Edwards Lifesciences from a “hold” rating to a “buy” rating and increased their price target for the stock from $75.00 to $90.00 in a research note on Thursday, January 30th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the company a “neutral” rating in a research note on Friday, October 25th. One research analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $79.71.

Edwards Lifesciences Stock Up 6.9 %

Shares of Edwards Lifesciences stock opened at $75.83 on Wednesday. The stock has a market capitalization of $44.72 billion, a price-to-earnings ratio of 10.94, a PEG ratio of 3.64 and a beta of 1.10. Edwards Lifesciences has a twelve month low of $58.93 and a twelve month high of $96.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The business’s 50 day simple moving average is $72.47 and its 200-day simple moving average is $69.32.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. Equities research analysts forecast that Edwards Lifesciences will post 2.56 earnings per share for the current year.

Insider Buying and Selling at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 2,500 shares of the company’s stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $74.08, for a total value of $185,200.00. Following the completion of the sale, the vice president now owns 23,189 shares in the company, valued at approximately $1,717,841.12. This represents a 9.73 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.29% of the company’s stock.

Institutional Trading of Edwards Lifesciences

Several hedge funds and other institutional investors have recently modified their holdings of EW. Alpha Financial Partners LLC purchased a new stake in shares of Edwards Lifesciences during the third quarter worth $693,000. Koshinski Asset Management Inc. bought a new position in shares of Edwards Lifesciences in the third quarter worth about $396,000. Vontobel Holding Ltd. raised its stake in Edwards Lifesciences by 5.7% during the 3rd quarter. Vontobel Holding Ltd. now owns 439,106 shares of the medical research company’s stock valued at $28,977,000 after purchasing an additional 23,560 shares during the last quarter. nVerses Capital LLC acquired a new position in Edwards Lifesciences in the 3rd quarter valued at approximately $792,000. Finally, Trust Co. of Vermont lifted its holdings in shares of Edwards Lifesciences by 36.1% during the 3rd quarter. Trust Co. of Vermont now owns 3,019 shares of the medical research company’s stock worth $199,000 after acquiring an additional 801 shares during the period. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.